Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Migrating Needle in Right Ventricle Wall With Purulent Tamponade.

The American journal of case reports·2026
Same author

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Circulation·2026
Same author

FEV1 is a major prognostic factor in diverse heart failure populations: findings from the Global Heart Failure registry.

ESC heart failure·2026
Same author

Novel SCN5A variant associated with flecainide-responsive multifocal ventricular arrhythmia and recovered cardiomyopathy.

Journal of applied genetics·2026
Same author

Galectin-3 and Strain Imaging for Early Heart Failure Prediction After First Myocardial Infarction.

International journal of molecular sciences·2025
Same author

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

The New England journal of medicine·2025

相关实验视频

Updated: Jun 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

fondaparinux 对急性ST段升高心肌梗塞患者的死亡率和再发作的影响:OASIS-6随机试验.

Salim Yusuf1, Shamir R Mehta, Susan Chrolavicius

  • 1Department of Medicine, McMaster University and Hamilton Health Sciences, McMaster Clinic, Hamilton General Hospital, Hamilton, Ontario, Canada. yusufs@mcmaster.ca

JAMA
|March 16, 2006
PubMed
概括
此摘要是机器生成的。

在ST段升高心肌梗塞 (STEMI) 患者中,芬达巴努克斯显著降低了死亡和再发病率. 这种XA因子抑制剂被证明是有益的,特别是对于那些没有接受初级皮肤冠状动脉干预的人来说,而不会增加出血风险.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

相关实验视频

Last Updated: Jun 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 尽管取得了进展,急性ST段升高心肌梗塞 (STEMI) 的死亡率仍然很高.
  • 额外的抗血栓剂在STEMI治疗中的作用,特别是在没有接受再输血治疗的患者中,仍然不清楚.

研究的目的:

  • 与STEMI患者的通常护理相比,评估早期启动的 fondaparinux (XA因子抑制剂) 在长达8天的疗效和安全性.
  • 评估芬达巴努克斯对各种STEMI治疗小组的死亡率和复发率的影响.

主要方法:

  • 这是一项随机,双盲,安慰剂对照试验,涉及41个国家的12,092名STEMI患者.
  • 患者接受芬达巴林克斯 (每天2.5毫克) 或对照剂 (安慰剂或未分离的肝素,其次是安慰剂) 长达8天.
  • 主要终点是30天死亡或心脏复发的复合结果,9天和3-6个月的二次评估.

主要成果:

  • 芬达巴林克斯显著降低了30天复合的死亡或再发病率 (11.2%对9.7%,P = .008).
  • 益处在9天和最后的随访时持续,在整个研究期间,死亡率显著降低.
  • 芬达巴鲁努克斯在一个亚组中表现出优于未分离的肝素,在接受血栓消毒疗法或不接受再输血疗法的患者中表现出显著的益处;在初级PCI患者中没有发现益处.
  • 随着 fondaparinux 的使用,人们观察到较少的严重出血和显著减少的心脏栓塞的趋势.

结论:

  • 芬达巴努克斯显著降低了STEMI患者的死亡率和再发病率,特别是那些没有接受初级皮肤穿刺冠状动脉干预的患者.
  • 该药物表现出良好的安全性,没有增加出血或中风.
  • 早期服用芬达帕鲁努克斯是一种有价值的治疗选择,用于STEMI管理.